Anebulo Pharmaceuticals (ANEB) Interest & Investment Income (2022 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Interest & Investment Income of $85410.0 for Q4 2025, up 1108.58% year-over-year from $7067.0 in Q4 2024, and down 22.08% quarter-over-quarter from $109616.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Interest & Investment Income (2022 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Interest & Investment Income for 4 consecutive years, with $85410.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest & Investment Income rose 1108.58% year-over-year to $85410.0; the TTM figure through Dec 2025 stood at $419866.0 (up 177.37% YoY), while the FY2025 annual figure was $257913.0, up 3.57% from the prior year.
- Interest & Investment Income eased to $85410.0 in Q4 2025 per ANEB's latest filing, from $109616.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $122583.0 in Q2 2025 and bottomed at $6.0 in Q2 2023.
- Historically, Interest & Investment Income has averaged $60764.2 across 4 years, with a median of $68084.0 in 2024.
- On a YoY basis, Interest & Investment Income climbed as much as 836866.67% in 2024 and fell as far as 90.64% in 2024.
- Anebulo Pharmaceuticals' Interest & Investment Income stood at $8816.0 in 2022, then jumped by 756.65% to $75522.0 in 2023, then slumped by 90.64% to $7067.0 in 2024, then jumped by 1108.58% to $85410.0 in 2025.
- Business Quant data shows ANEB's Interest & Investment Income at $85410.0 in Q4 2025, $109616.0 in Q3 2025, and $122583.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 85,410.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 85,410.00 |
| Sep 30, 2025 | 109,616.00 |
| Jun 30, 2025 | 122,583.00 |
| Mar 31, 2025 | 102,257.00 |
| Dec 31, 2024 | 7,067.00 |
| Sep 30, 2024 | 26,006.00 |
| Jun 30, 2024 | 50,218.00 |
| Mar 31, 2024 | 68,084.00 |
| Dec 31, 2023 | 75,522.00 |
| Sep 30, 2023 | 55,198.00 |
| Jun 30, 2023 | 6.00 |
| Mar 31, 2023 | 79,152.00 |
| Dec 31, 2022 | 8,816.00 |